{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:57:58Z","timestamp":1790873878768,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>L-type amino acid transporter-1 (LAT1) is a tumor-specific transporter expressed in various tumor types, with minimal expression in normal organs. We previously demonstrated <jats:sup>18<\/jats:sup>F-fluoro-borono-phenylalanine (<jats:sup>18<\/jats:sup>F-FBPA) as a selective PET probe for LAT1 in a preclinical study. Herein, we evaluated LAT1 expression in preoperative patients with lung or mediastinal tumors using <jats:sup>18<\/jats:sup>F-FBPA PET and immunofluorescence staining.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>The study population included patients with histopathological diagnosis (n = 55): primary lung cancers (n = 21), lung metastases (n = 6), mediastinal tumors (n = 15), and benign lesion (n = 13). PET scanning was performed 1 hour after the injection of <jats:sup>18<\/jats:sup>F-FBPA (232 \u00b1 32 MBq). Immunofluorescence staining was performed on the resected tumor sections using LAT1 antibody. LAT1 staining was graded on a 4-grade scale and compared with the SUV<jats:sub>max<\/jats:sub> on <jats:sup>18<\/jats:sup>F-FBPA PET.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A positive correlation was observed between the SUV<jats:sub>max<\/jats:sub> of <jats:sup>18<\/jats:sup>F-FBPA PET and LAT1 expression by immunofluorescence staining (<jats:italic toggle=\"yes\">r<\/jats:italic> = 0.611, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The SUV<jats:sub>max<\/jats:sub> of <jats:sup>18<\/jats:sup>F-FBPA was 3.92 \u00b1 1.46 in grade 3, 3.21 \u00b1 1.82 in grade 2, 2.33 \u00b1 0.93 in grade 1, and 1.50 \u00b1 0.39 in grade 0 of LAT1 expression. Although <jats:sup>18<\/jats:sup>F-FBPA PET showed variable uptake in lung cancers and mediastinal tumors, benign lesions showed significantly lower SUV<jats:sub>max<\/jats:sub> than those in malignant lesions (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Uptake on <jats:sup>18<\/jats:sup>F-FBPA PET reflected the expression level of LAT1 in lung and mediastinal tumors. It was suggested that <jats:sup>18<\/jats:sup>F-FBPA PET can be used for the precise characterization of the tumor in pretreatment evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004816","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T16:00:31Z","timestamp":1694188831000},"page":"853-860","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors"],"prefix":"10.1097","volume":"48","author":[{"given":"Tadashi","family":"Watabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ose","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahiro","family":"Naka","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanou","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Funaki","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Radiology, Osaka University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Radiology, Osaka University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kurimoto","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayako","family":"Isohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eku","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Ohgaki","sequence":"additional","affiliation":[{"name":"Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Kanai","sequence":"additional","affiliation":[{"name":"Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shintani","sequence":"additional","affiliation":[{"name":"Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12149-019-01347-8","article-title":"4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research","volume":"33","year":"2019","journal-title":"Ann Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s12149-016-1121-8","article-title":"Assessment of 10B concentration in boron neutron capture therapy: potential of image-guided therapy using 18FBPA PET","volume":"30","year":"2016","journal-title":"Ann Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13550-014-0070-2","article-title":"FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model","volume":"4","year":"2014","journal-title":"EJNMMI Res"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00259-016-3487-1","article-title":"18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-methionine PET","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"107964","DOI":"10.1016\/j.pharmthera.2021.107964","article-title":"Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics","volume":"230","year":"2022","journal-title":"Pharmacol Ther"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1349-7006.2008.00969.x","article-title":"l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms","volume":"99","year":"2008","journal-title":"Cancer Sci"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.2012.310","article-title":"Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer","volume":"107","year":"2012","journal-title":"Br J Cancer"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12149-018-1296-2","article-title":"Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [18F]fluoro-borono-phenylalanine PET\/CT","volume":"32","year":"2018","journal-title":"Ann Nucl Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/RLU.0000000000003274","article-title":"18F-FBPA PET in sarcoidosis: comparison to inflammation-related uptake on FDG PET","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s41824-022-00156-z","article-title":"Exploration of the threshold SUV for diagnosis of malignancy using 18F-FBPA PET\/CT","volume":"6","year":"2022","journal-title":"Eur J Hybrid Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","year":"2020","journal-title":"Invest New Drugs"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.18632\/oncotarget.27552","article-title":"Targeted alpha therapy using astatine (211At)-labeled phenylalanine: a preclinical study in glioma bearing mice","volume":"11","year":"2020","journal-title":"Oncotarget"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/cas.14761","article-title":"\u03b1-Emitting cancer therapy using 211 At-AAMT targeting LAT1","volume":"112","year":"2021","journal-title":"Cancer Sci"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13139-021-00719-1","article-title":"Improved stability and practicality for synthesis of 4-borono-2-[18F]fluoro-l-phenylalanine by combination of [18O]O2 single-use and [18F]CH3COOF labeling agents","volume":"56","year":"2022","journal-title":"Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1097\/00001756-200011090-00021","article-title":"Expression of a system L neutral amino acid transporter at the blood-brain barrier","volume":"11","year":"2000","journal-title":"Neuroreport"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40170-022-00295-8","article-title":"Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1","volume":"10","year":"2022","journal-title":"Cancer Metab"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2023.41.4_suppl.494","article-title":"Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study. 2023 ASCO GI Cancers Symposium","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.bjc.6604235","article-title":"Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer","volume":"98","year":"2008","journal-title":"Br J Cancer"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/hepr.12431","article-title":"Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma","volume":"45","year":"2015","journal-title":"Hepatol Res"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-017-3477-4","article-title":"Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma","volume":"81","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1349-7006.2011.02151.x","article-title":"Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis","volume":"103","year":"2012","journal-title":"Cancer Sci"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02988521","article-title":"Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)\u2014usefulness and limitations in \u201cclinical reality\u201d","volume":"17","year":"2003","journal-title":"Ann Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.rlu.0000082664.22354.4b","article-title":"F-18 FDG positron emission tomographic imaging in a case of ruptured breast implant: inflammation or recurrent tumor?","volume":"28","year":"2003","journal-title":"Clin Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.3390\/cancers13194946","article-title":"FAP and FAPI-PET\/CT in malignant and non-malignant diseases: a perfect symbiosis?","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"109019","DOI":"10.1016\/j.apradiso.2019.109019","article-title":"Comparison of 18FBPA uptake with 18FDG uptake in cancer patients","volume":"157","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"bib27-20250621","first-page":"1329","article-title":"Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study","volume":"33","year":"2023","journal-title":"Eur Radiol"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1026608","DOI":"10.3389\/fonc.2022.1026608","article-title":"Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: comparison to FDG PET","volume":"12","year":"2022","journal-title":"Front Oncol"},{"key":"bib29-20250621","first-page":"20220463","article-title":"Non-oncologic incidental uptake on FAPI PET\/CT imaging","volume":"96","year":"2022","journal-title":"Br J Radiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:00:33Z","timestamp":1750532433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004816"}},"subtitle":["18F-FBPA PET Study With Immunohistological Comparison"],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004816","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}